Martin Shkreli: Biography, Career, and Business Insights

Martin Shkreli’s Profile Summary

Company	Pharmaceutical Fraud
Position	Operator
Source of wealth	Profits from hedge funds Elea Capital, MSMB Capital Management, and MSMB Healthcare; earnings as CEO of Retrophin and Turing Pharmaceuticals
Also known as	"Pharma Bro," convicted felon, former hedge fund manager.
Age	42
Education	Hunter College High School – diploma, Baruch College – Bachelor of Business Administration
Citizenship	United States
Residence	New York City, United States
Family	Information about his family is not publicly disclosed.
Website, Social Media	https://en.wikipedia.org/wiki/Martin_Shkreli

Martin Shkreli’s biography

Martin Shkreli, born on March 17, 1983, in Brooklyn, New York, is an American entrepreneur and former hedge fund manager. He co-founded hedge funds Elea Capital, MSMB Capital Management, and MSMB Healthcare, and served as CEO of pharmaceutical firms Retrophin and Turing Pharmaceuticals. Shkreli gained notoriety in 2015 when Turing Pharmaceuticals acquired the antiparasitic drug Daraprim and raised its price from $13.50 to $750 per pill, leading to widespread public and governmental criticism. In 2017, he was convicted of securities fraud and conspiracy to commit securities fraud, resulting in a seven-year prison sentence and financial penalties. He was released from prison in May 2022.

How did Martin Shkreli make money?

Martin Shkreli makes money in the following areas:

Profits from hedge funds Elea Capital, MSMB Capital Management, and MSMB Healthcare; earnings as CEO of Retrophin and Turing Pharmaceuticals
What is Martin Shkreli net worth?

As of 2025, there is no publicly available and reliable information regarding Martin Shkreli’s net worth.

What is Martin Shkreli also known as?

Martin Shkreli earned the nickname "Pharma Bro" following the controversial price hike of Daraprim, which led to public outrage and media scrutiny. His conviction for securities fraud further solidified his reputation as a convicted felon. Prior to these events, he was recognized as a hedge fund manager, co-founding and managing multiple investment funds focused on the healthcare sector.

Prominent achievements of Martin Shkreli

Co-founded multiple hedge funds and pharmaceutical companies, led Turing Pharmaceuticals' acquisition and controversial repricing of Daraprim, amassed a peak net worth of approximately $70 million, purchased the sole copy of Wu-Tang Clan's album "Once Upon a Time in Shaolin" for $2 million.

What are Martin Shkreli’s key insights?

Martin Shkreli's business approach has been characterized by aggressive investment strategies, a focus on undervalued pharmaceutical assets, and a willingness to implement significant price increases on acquired drugs to maximize profits. His methods have sparked ethical debates and legal challenges, highlighting the tension between profit motives and public health responsibilities.

Martin Shkreli’s personal life

Details regarding Martin Shkreli's family members are

Useful insights

Top 3 Financial Pyramid Schemes

As an expert at Traders Union, I can’t stress enough how critical it is to thoroughly research any financial opportunity before you invest. Taking a few extra steps in verifying the legitimacy of a platform or broker can save you from falling victim to scams.

Bernie Madoff

His $65 billion Ponzi scheme ran for decades, fooling banks, pension funds, and celebrities alike. He used new deposits to pay old investors, maintaining the illusion of steady returns.
Allen Stanford

Promised high yields through offshore “certificates of deposit,” but in reality, siphoned $7 billion from clients in what the SEC called a classic Ponzi structure.
Tom Petters

Forged documents to attract billions in fake consumer electronics deals. Investors believed they were financing orders for retailers like Costco and Best Buy.

One clear principle emerges from these cases: If returns are steady, unusually high, and come with little transparency—be extremely cautious. Real investments always include risk and regulatory oversight.